QU
uniQure
QURE · NASDAQ
$44.51 -0.96% (-$0.43)
1M -7.21%
Market Cap $3.09B
P/E Ratio -
Div. Yield -
ROE 111.96%
Piotroski F-Score Weak
3/9Valuation
0 /100
Expensive P/B 9.53x
P/S 165.35x
P/FFO N/A
Growth
0 /100
Declining Book val. growth 25.24%
Rev. growth 46.73%
FCF growth N/A
Profitability
7 /100
Weak Op. margin 1,089.06%
Gross margin 22.79%
FCF margin 862.32%
Quality
0 /100
Poor ROA 25.60%
ROIC 23.12%
Asset turnover 0.02x
Debt
69 /100
Low Int. coverage -3.28x
Debt/Equity 0.19x
Current ratio 10.01x
Stability
25 /100
Unstable EPS volatility 95.63%
Beta 0.94x
Profitable years 0
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o QURE
Online
O podjetju
uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.
V vašem jeziku še ni na voljo, zato je besedilo v angleščini.
Sector
Healthcare
Industry
Biotechnology
CEO
Matthew C. Kapusta
Employees
221
Headquarters
Amsterdam
Prihajajoči dogodki
09 NOV.
Earnings
Upcoming earnings report